Recent advances in treatment of advanced urothelial carcinoma. - Wikidata - wikimedia - TriplyDB

Recent advances in treatment of advanced urothelial carcinoma.

Recent advances in treatment of advanced urothelial carcinoma.

http://www.wikidata.org/entity/Q33565845

about

Does occupational exposure to solvents and pesticides in association with glutathione S-transferase A1, M1, P1, and T1 polymorphisms increase the risk of bladder cancer? The Belgrade case-control study A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.Systemic therapy for bladder cancer - a medical oncologist's perspective.Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.Induction of apoptosis by sinulariolide from soft coral through mitochondrial-related and p38MAPK pathways on human bladder carcinoma cells Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI.MicroRNA-148a represents an independent prognostic marker in bladder cancer.Flaccidoxide-13-Acetate Extracted from the Soft Coral Cladiella kashmani Reduces Human Bladder Cancer Cell Migration and Invasion through Reducing Activation of the FAK/PI3K/AKT/mTOR Signaling Pathway.A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.

P2860

Q28387599-1B084415-9A79-4D95-B660-8EB935FA339A Q33407440-70652724-FFB3-4322-9292-67CFC4205A69 Q34516731-9B9307D4-9EBF-4162-9ACB-F40EC78D1D74 Q35049486-A4724DE0-B25E-4F7D-8EC7-3A4AD2B205E3 Q36145468-5F1FE5E3-EA0F-416E-9C34-95E3252DA7D8 Q36265434-5D2E8EEC-B0F4-4A5B-AE4F-B520CCF028D9 Q36482384-D4AF284B-368E-4B27-A45A-433F62B9C308 Q38735342-79B98839-5084-45DE-9459-9F1E885CB3D0 Q39005742-D19C656F-0A01-42E2-B25F-D6A926C99811 Q39254614-E48D4908-A697-40CE-BBF5-18093A2468A7 Q41024564-76E5183B-5B24-4AF7-BEB5-3448442EF8DF Q47252118-713C60B6-23B6-48FA-906C-95BD4AA3EDE1 Q48154177-AC898657-7F48-45B6-9C3F-495D876DBDDC

P2860

Recent advances in treatment of advanced urothelial carcinoma.

http://www.wikidata.org/entity/Q33565845

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Recent advances in treatment of advanced urothelial carcinoma.

@ast

Recent advances in treatment of advanced urothelial carcinoma.

@en

Recent advances in treatment of advanced urothelial carcinoma.

@nl

type

label

Recent advances in treatment of advanced urothelial carcinoma.

@ast

Recent advances in treatment of advanced urothelial carcinoma.

@en

Recent advances in treatment of advanced urothelial carcinoma.

@nl

prefLabel

Recent advances in treatment of advanced urothelial carcinoma.

@ast

Recent advances in treatment of advanced urothelial carcinoma.

@en

Recent advances in treatment of advanced urothelial carcinoma.

@nl

P1433

Q33565845-A687DBDF-3565-44D4-B54E-1C6998932473

P1476

Q33565845-DB9A7160-9668-40A4-91C8-6CCE301B38E6

P2093

Q33565845-913589B8-EAA1-46A0-82D7-6925EFFD317E

P2860

Q33565845-000FAA68-A70B-4588-B187-7F5556A8831B

Q33565845-0C984E38-6141-4472-B1B1-7B06789E995D

Q33565845-210E6F91-A44A-4381-B1AC-45C2E03B8024

Q33565845-23EF105C-FF98-4A7E-9895-A124183A6E1D

Q33565845-389AC6E4-B7EF-4FA9-86BF-9130E7929465

Q33565845-3C1C4B5D-1F4D-4C5D-9467-3505BB44397B

Q33565845-3EE05B2C-F8EA-4B58-875E-AA726C3CA89A

Q33565845-3EE6A1E7-98F6-462C-B701-DFD46CCB80B1

Q33565845-4F5A100B-0035-49DC-A5A3-A2F2C4853199

Q33565845-6326329F-ADF9-49EF-8D3F-3149FB78A801

P2888

Q33565845-2D2C65C2-ADA8-491A-B2BC-B2B59BC66F45

P304

Q33565845-3F8246FC-59DC-4A45-BD31-750FC88400D8

P31

Q33565845-EFA1E696-B5F4-4B80-99CF-BCDA13E2BBD6

P356

Q33565845-6E514787-1228-4FD1-9DE3-3804696FE37D

P433

Q33565845-8159EA23-E785-46BF-A203-5F2470687F07

P478

Q33565845-E4BB63C3-8CA8-4F9D-AF38-347107FDBFAE

P577

Q33565845-9D1F4E0C-A587-4809-B8F4-ED2AAA0D709F

P6179

Q33565845-F6F06387-2E1B-454B-A8DE-8B5C423B9F2B

P698

Q33565845-1FD08480-5277-41B9-BC11-18C7FC3675F2

P932

Q33565845-E7B951A6-E381-4400-BEA0-1361F8D52A9F

P356

S11934-012-0238-0

P1433

Current urology reports

P1476

Recent advances in treatment of advanced urothelial carcinoma.

@en

P2093

Jenny J Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic implications of p53 gene mutations in bladder tumors.

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

NY-ESO-1: review of an immunogenic tumor antigen.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

P2888

s11934-012-0238-0

P304

147-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-012-0238-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021687202

http://www.w3.org/2001/XMLSchema#string

P698

22367511

http://www.w3.org/2001/XMLSchema#string

P932

4009980

http://www.w3.org/2001/XMLSchema#string